Immune cells expressing membrane-bound interleukin 15 (mbIL15) and uses thereof
The present invention provides, in certain aspects, a natural killer (NK) cell that expresses all or a functional portion of interleukin-15 (IL-15), and methods for producing such cells. The invention further provides methods of using a natural killer (NK) cell that expresses all or a functional portion of interleukin-15 (IL-15) to treat cancer in a subject or to enhance expansion and/or survival of NK cells.
1. A method of treating a cancer, the method comprising:
administering to a subject having the cancer a population of cells that express all or a functional portion of interleukin-15 (IL-15), wherein the all or a functional portion of the IL-15 is fused to all or a portion of a transmembrane protein and results in the IL-15 being expressed as a cell membrane-bound polypeptide (mbIL15) on the surface of the cells,
wherein the transmembrane protein is a CD8 transmembrane domain, and
wherein the mbIL15 has the sequence of SEQ ID NO: 2.
2. The method of claim 1 , wherein the population of cells comprises one or more of natural killer (NK) cells, T-cells, dendritic cells and monocytes.
3. The method of claim 2 , wherein the population of cells comprises isolated CD56+CD3 − natural killer cells.
4. The method of claim 1 , wherein the mbIL15 activates IL-15 signaling and/or anti-apoptotic signaling in an autocrine manner.
5. The method of claim 1 ,
wherein the immune cells expressing mbIL15 exhibit enhanced expression of one or more activation receptors as compared to immune cells not expressing mbIL15, wherein the one or more activation receptors are selected from NKG2D, NKp44 (CD336) and NKp30 (CD337), CD16 or CD56.
6. The method of claim 1 , wherein the cancer is selected from leukemia, a myelodysplastic syndrome, a lymphoma, a solid tumor or a sarcoma.
7. The method of claim 6 , wherein the cancer is a leukemia, and wherein the leukemia is acute lymphoblastic leukemia, acute myeloid leukemia, chronic myelogenous leukemia, or chronic lymphocytic leukemia.
8. The method of claim 1 , further comprising administering IL-2 to the individual.
9. The method of claim 8 , wherein the IL-2 is administered at a dose of 1 million IU/m 2 or less.
10. The method of claim 1 , further comprising administering one or more antibodies directed against the cancer to the individual.
11. A method of treating cancer, the method comprising:
administering to a subject having the cancer a population of immune cells that expresses all or a functional portion of interleukine-15 (IL15) fused to all or a functional portion of a transmembrane domain of a transmembrane protein, resulting in the IL-15 being expressed as a membrane-bound IL-15 (mbIL15) on the surface of the immune cells,
wherein the mbIL15 has the sequence of SEQ ID NO:2,
wherein the population of cells comprises one or more of natural killer (NK) cells, T-cells, dendritic cells and monocytes, and wherein the mbIL15 promotes one or more of:
(i) natural killer (NK) cell survival,
(ii) regulation of NK cell and T-cell activation and proliferation, and
(iii) support of NK cell development from hematopoietic stem cells.
12. The method of claim 11 , wherein the all or a functional portion of the transmembrane domain is from a CD8α transmembrane protein.
13. The method of claim 11 , wherein the all or a functional portion of the IL-15 comprises all or a functional portion of the amino acid sequence of SEQ ID NO: 4.
14. The method of claim 11 , wherein the population of cells exhibits enhanced phosphorylation of one or more of STAT1, STAT3 and STATS, Src, Erkl/2 or Mek as compared to a population of cells not expressing mbIL15, and wherein the population of cells expressing mbIL15 exhibits enhanced anti-apoptotic signaling as compared to a population of cells not expressing mbIL15.
15. A method of treating a cancer, comprising administering to a subject having the cancer a population of immune cells that expresses a membrane-bound interleukin 15 (mbIL15), wherein the mbIL15 comprises the amino acid sequence of SEQ ID NO: 2,
wherein the population of cells comprises one or more of natural killer (NK) cells, T-cells, dendritic cells and monocytes, and wherein the mbIL15 promotes one or more of:
(i) natural killer (NK) cell survival,
(ii) regulation of NK cell and T cell activation and proliferation, and
(iii) support of NK cell development from hematopoietic stem cells.
16. A method of treating a cancer, the method comprising:
administering to a subject having the cancer a population of immune cells that expresses all or a functional portion of interleukin-15 (IL-15) as a cell membrane-bound polypeptide (mbIL15), wherein mbIL15 comprises the amino acid sequence of SEQ ID NO. 2.
17. The method of claim 16 , further comprising administering IL-2 to the individual.
18. The method of claim 16 , wherein the cancer is selected from leukemia, a myelodysplastic syndrome, a lymphoma, a solid tumor or a sarcoma.